# Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159

> **NCT05082779** · PHASE1 · COMPLETED · sponsor: **Cascade Pharmaceuticals, Inc** · enrollment: 79 (actual)

## Conditions studied

- Primary Sclerosing Cholangitis (PSC)

## Interventions

- **DRUG:** CS0159

## Key facts

- **NCT ID:** NCT05082779
- **Lead sponsor:** Cascade Pharmaceuticals, Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-26
- **Primary completion:** 2022-09-16
- **Final completion:** 2022-10-12
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2022-10-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05082779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05082779, "Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05082779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*